drugset / Trial / NCT04306900
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Timeline
- Start
- 2020-03-30
- Primary completion
- 2022-11-30
- Completion
- 2024-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budigalimab | Monoclonal antibody | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | TTX-030 | Unknown | — | — |